RNA-Based Technology Found to Shape the Future of Therapeutic Antibodies

Antibodies used for the treatment of various diseases are found to be one of the great success stories of 21st - century medicine. Around five out of the ten top-selling pharmaceuticals include antibody products in the United States.

Antibodies are //made of large, complex proteins which can be expensive for manufacturing. A research team from the Perelman School of medicine from the University of Pennsylvania has demonstrated a new way to deliver safe and cost-effective therapeutic antibodies.

Tumor Markers - For Cancer Diagnosis and Prognosis - Antigens and Antibodies as Tumor Markers
Cancer-specific antigens and antibodies are successfully employed as tumor markers.

‘Powerful RNA-based technology was found to be a new way of delivering safe and cost-effective therapeutic antibodies.’

Tweet it Now

The technique was found to involve the use of injections with messenger RNAs (mRNAs), this serves as a blueprint molecule which can cause the cells to manufacture proteins. The mRNA molecules are being taken up by the cells in the body which later become factories for developing proteins. Therefore, antibody proteins are encoded by the mRNAs.

These mRNAs are modified so they can easily enter cells and not activate inflammatory molecules that lead to adverse events. Researchers have previously shown that they can use this method to make hormones and other proteins in lab animals. In the new study, reported today in Nature Communications, the Penn-led team demonstrated that the mRNA method can be used to make antibody proteins--enough to confer vaccine-like protection against HIV with one, small dose--in mice.

"We showed that you can give 1/40th the dose of mRNA compared to the antibody protein itself, and completely protect mice from HIV infection when they are exposed to the virus," said senior author Drew Weissman, MD, PhD, a professor of Infectious Diseases. "Clinical trials of this anti-HIV antibody are already underway, but we think our mRNA approach could in principle be a very effective alternative to this and other antibody therapies."

Antibodies in Patients With Rare Disorder may Prevent Type 1 Diabetes and Psoriasis
The antibodies were derived from people with a rare autoimmune disorder, called autoimmune polyendocrine syndrome type 1 (APECED).

The basic idea of injecting mRNA into patients to make therapeutic proteins in their cells has been around for a long time, but ordinary mRNA doesn't work well for this application. After standard mRNA is injected, enzymes and the immune system tend to treat it like an invading virus and make inflammatory proteins and responses that could make patients sick along with other adverse events.

However, in a series of papers starting in 2005,Weissman, co-developer Katalin Karikó, PhD, now an adjunct associate professor of Neurosurgery and vice president of BioNTech RNA Pharmaceuticals, and colleagues reported that ordinary mRNAs could be modified in relatively straightforward ways so that they do not activate inflammatory pathways and can efficiently produce large amounts of protein for an extended amount of time. This team, along with lead author Norbert Pardi, PhD, a postdoctoral research associate in the Weissman lab, and Michael Hogan, a pre-doctoral student at Penn, recently published the use of nucleoside-modified mRNA complexed to lipid nanoparticles as a vaccine for Zika in the journal Nature.

Broadly Neutralizing HIV Antibodies Engineered to be Better Vaccine Leads
Broadly neutralizing antibodies are rare, unusual antibodies that result from continuous mutational adaptation driven by the evolution of HIV in the body over time.

Production of therapeutic proteins via mRNAs within a patient's own cells may be safer, in many cases, than the production of the proteins in a biotech facility. "Biotech manufacturing requires a cell line and extensive purification that can aggregate or misfold the protein, resulting in an unwanted immune response against the protein or other adverse events," Weissman said.

In the current study, the researchers demonstrated the therapeutic potential of modified mRNAs that code for the anti-HIV antibody VRC01.

Development of Therapeutic Monoclonal Antibodies to Fight Cancer
A new cancer treatment that is highly selective in blocking the action of faulty matrix metalloproteinases (MMPs) has been developed by researchers.

Most antibodies produced in response to HIV infection are ineffective at stopping the ever-changing virus. By contrast, VRC01--first isolated from a human HIV-positive volunteer--hits a well conserved target on multiple HIV strains and thus neutralizes about 90 percent of HIV strains. Other researchers are now developing VRC01 as a possible therapy for people who already have HIV infection or as a passive vaccine to protect uninfected people. However, the likely high cost of the VRC01 antibody therapy could present an obstacle to its widespread use.

Weissman, Pardi, and colleagues showed that a single injection of the mRNAs that encode the VRC01 monoclonal antibody led to robust production of the resulting antibody protein in the livers of mice within 24 hours. A small weekly injection was enough to maintain high levels VRC01 antibody levels in the circulation.

Most importantly, the scientists showed that a single 30- or 15-microgram injection of VRC01 mRNA was enough to protect mice, which had been engineered to be infectable by HIV--from intravenous exposure to two reference strains of HIV.

For comparison, the team showed that when they directly injected VRC01 antibodies into the same mice, 600 micrograms was needed to provide the same level of protection against HIV.

"This is the first proof-of-principal demonstration of mRNAs in a truly therapeutic role and as a replacement for antibodies," Weissman said.

Source-Eurekalert